Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2025 13:50 ET | Source: GRI Bio, Inc.

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
May 01, 2025 09:25 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s...
March 04, 2025 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad,...
October 30, 2024 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

Access the Virtual Investor “What This Means” Segment here THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical...
July 18, 2024 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared ablation technology from RF Innovations, Inc. THE WOODLANDS, TX, July 18, 2024 (GLOBE...
July 11, 2024 09:20 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE...
May 22, 2024 09:15 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to...